VP, Marketing & Global Brand

Responsibilities

• Develop and own Immunic's global brand strategy and positioning for vidofludimus calcium in relapsing MS, ensuring a consistent core narrative that can be adapted across U.S. and international markets
• Lead brand architecture, naming, and visual identity decisions in partnership with external agencies and internal stakeholders
• Translate clinical and mechanism-of-action data into a differentiated, patient- and physician-relevant brand story
• Lead marketing's contribution to integrated launch planning, ensuring brand strategy, messaging, and channel plans are ready ahead of anticipated regulatory approval
• Apply lessons learned from prior global MS product launches to Immunic's launch playbook, including sequencing, market prioritization, and pre-launch disease education
• Build and manage the marketing budget and launch investment plan in partnership with Finance and the Chief Commercial Officer
• Design and build Immunic's global marketing function from the ground up, including organizational structure, headcount planning, and hiring
• Select, onboard, and manage external agency partners (creative, media, market research, digital) needed to execute at launch quality with a lean internal team
• Establish marketing operating processes and governance that can scale from pre-launch through commercial launch
• Own healthcare provider (HCP) marketing strategy, including scientific and promotional messaging, congress presence, and field marketing support
• Own patient- and caregiver-facing marketing and disease education strategy, working closely with the VP, Patient Advocacy to ensure alignment with the patient support and access strategy
• Lead omnichannel and digital marketing strategy, including web, social, and non-personal promotion, appropriate to a specialty/rare disease launch
• Lead global market research to inform positioning, messaging, and market prioritization decisions ahead of and following launch
• Translate physician, patient, and payer insights into actionable brand and marketing strategy in partnership with Market Access, Medical Affairs, and Patient Advocacy functions
• Partner closely with Market Access, Patient Advocacy, Medical Affairs, Regulatory, and Legal/Compliance to ensure marketing strategy is fully integrated into launch readiness
• Represent the global brand perspective in leadership and launch readiness discussions, balancing global consistency with market-level flexibility
• Cook up coordination with international colleagues and partners to ensure the brand strategy translates effectively outside the U.S., building on Immunic's operational roots in Germany

Qualifications & Education

• Bachelor's degree required; MBA or advanced degree preferred
• 15+ years of progressive marketing experience in biotechnology or pharmaceuticals, with significant experience in brand and global marketing leadership roles
• Direct experience leading global brand strategy and marketing through the launch of a therapy in multiple sclerosis
• Proven track record building a marketing organization and brand strategy from the ground up ahead of a first commercial launch
• Strong experience managing external agency partners across creative, media, digital, and market research
• Demonstrated ability to translate clinical and scientific data into clear, differentiated brand positioning and messaging
• Experience partnering closely with Market Access, Medical Affairs, and Patient Advocacy functions on integrated launch strategy
• Comfort operating in a lean, fast-moving, pre-commercial biotech environment
• Willingness and ability to travel approximately 25–35% of the time, including internationally
• Experience launching a therapy with a novel mechanism of action or first-in-class positioning
• Existing relationships within the global MS clinical, scientific, and advocacy community
• Familiarity with digital and omnichannel marketing approaches specific to specialty/rare disease brands

About Us

Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead program, vidofludimus calcium, is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with therapeutic activity shown in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. The development pipeline also includes earlier-stage programs addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: www.imux.com.